2010
Comparison of Catheterization Laboratory Initiated Abciximab and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes (an ACUITY Substudy)
Kirtane AJ, Parise H, Mehran R, Moses JW, Fahy M, Bertrand ME, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Ware JH, Pocock SJ, Lansky AJ, Stone GW. Comparison of Catheterization Laboratory Initiated Abciximab and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes (an ACUITY Substudy). The American Journal Of Cardiology 2010, 106: 180-186. PMID: 20599000, DOI: 10.1016/j.amjcard.2010.03.015.Peer-Reviewed Original ResearchConceptsAcute coronary syndromePercutaneous coronary interventionCoronary syndromeCoronary interventionTreatment selectionHigh-risk acute coronary syndromesUrgent Intervention Triage Strategy (ACUITY) trialGlycoprotein IIb/IIIa inhibitorsBaseline cardiac risk factorsNet clinical adverse eventsIIb/IIIa inhibitorsPrevious revascularization proceduresUse of abciximabCardiac risk factorsStudy end pointClinical adverse eventsImproved clinical outcomesST-segment deviationAcute CatheterizationComposite ischemiaMajor bleedingIschemic complicationsAdverse eventsBiomarker elevationRevascularization procedures
2009
Impact of Gender and Antithrombin Strategy on Early and Late Clinical Outcomes in Patients With Non–ST-Elevation Acute Coronary Syndromes (from the ACUITY Trial)
Lansky AJ, Mehran R, Cristea E, Parise H, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Stone GW. Impact of Gender and Antithrombin Strategy on Early and Late Clinical Outcomes in Patients With Non–ST-Elevation Acute Coronary Syndromes (from the ACUITY Trial). The American Journal Of Cardiology 2009, 103: 1196-1203. PMID: 19406258, DOI: 10.1016/j.amjcard.2009.01.030.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdultAge FactorsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsCause of DeathDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationElectrocardiographyEnoxaparinFemaleFollow-Up StudiesHeparinHirudinsHumansMaleMiddle AgedPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProbabilityProportional Hazards ModelsRecombinant ProteinsReference ValuesRisk AssessmentSeverity of Illness IndexSex FactorsSurvival AnalysisTime FactorsTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsElevation acute coronary syndromePercutaneous coronary interventionAcute coronary syndromeComposite ischemiaNet clinical outcomeMajor bleedingCoronary syndromeClinical outcomesNet clinical adverse eventsIIb/IIIa inhibitorsLate clinical outcomesCoronary artery bypassClinical adverse eventsImpact of genderACUITY trialBivalirudin monotherapyAntithrombotic therapyArtery bypassNon–STAdverse eventsAntithrombotic strategiesCoronary interventionIschemiaBivalirudin